or Try an Advanced Search...

    Technical Analysis for ALGS - Aligos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 18.03 -7.37% -1.43
    ALGS closed down 7.37 percent on Friday, November 15, 2024, on 58 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ALGS trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Slingshot Bullish Bullish Swing Setup -7.37%
    Calm After Storm Range Contraction -7.37%
    Wide Range Bar Range Expansion -7.37%
    Parabolic Rise Strength -7.37%
    Upper Bollinger Band Walk Strength -7.37%
    Older End-of-Day Signals for ALGS ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 4 hours ago
    Down 10% about 7 hours ago
    Down 1 ATR about 7 hours ago
    2x Volume Pace about 9 hours ago
    1.5x Volume Pace about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALGS Chart by TradingView
    Basic chart:

    Profile

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection

    Is ALGS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 10 Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations
    Nov 6 Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
    Nov 6 Aligos Therapeutics files $400M mixed securities shelf
    Nov 6 Aligos Therapeutics EPS of -$3.07 misses by $1.75
    Nov 6 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
    Oct 30 Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
    Oct 15 Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
    Sep 30 Aligos Therapeutics to Present at Investor Conferences in October
    Sep 24 Aligos Therapeutics names Hardean Achneck as chief medical officer
    Sep 24 Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
    See more ALGS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 30.0
    52 Week Low 6.76
    Average Volume 249,507
    200-Day Moving Average 15.31
    50-Day Moving Average 10.37
    20-Day Moving Average 11.21
    10-Day Moving Average 13.77
    Average True Range 2.05
    RSI (14) 75.61
    ADX 44.79
    +DI 39.86
    -DI 11.15
    Chandelier Exit (Long, 3 ATRs) 15.75
    Chandelier Exit (Short, 3 ATRs) 13.23
    Upper Bollinger Bands 19.24
    Lower Bollinger Band 3.19
    Percent B (%b) 0.92
    BandWidth 143.18
    MACD Line 2.35
    MACD Signal Line 1.18
    MACD Histogram 1.1658
    Fundamentals Value
    Market Cap 1.3 Billion
    Num Shares 72 Million
    EPS -1.89
    Price-to-Earnings (P/E) Ratio -9.54
    Price-to-Sales 3.14
    Price-to-Book 0.93
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.00
    Resistance 3 (R3) 22.19 21.05 21.34
    Resistance 2 (R2) 21.05 20.04 20.96 21.12
    Resistance 1 (R1) 19.54 19.41 18.97 19.35 20.90
    Pivot Point 18.40 18.40 18.11 18.31 18.40
    Support 1 (S1) 16.89 17.39 16.32 16.70 15.16
    Support 2 (S2) 15.75 16.76 15.66 14.94
    Support 3 (S3) 14.24 15.75 14.71
    Support 4 (S4) 14.05